Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cisplatin + Dulanermin + Vinorelbine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
Dulanermin | AMG951|AMG-951|AMG 951|RG3639 | Dulanermin is a recombinant human Apo2L/Trail protein that potentially targets DR4 and DR5 to activate apoptotic pathways and reduce tumor growth (PMID: 29134432, PMID: 22914439). | ||
Vinorelbine | Navelbine | Vinorelbin | Antimicrotubule Agent 14 | Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04765709 | Phase II | Cisplatin + Dulanermin + Vinorelbine Carboplatin + Durvalumab + Vinorelbine Cisplatin + Durvalumab + Pemetrexed Disodium Carboplatin + Durvalumab + Pemetrexed Disodium | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE) | Active, not recruiting | ITA | FRA | ESP | 0 |